EndoChoice Receives FDA Clearance for Lumos With Adaptive Matrix Imaging

EndoChoice Holdings Inc. announced the recent U.S. Food and Drug Administration clearance and U.S. launch of Lumos with Adaptive Matrix Imaging. This proprietary imaging software system will now be part of the company’s Generation 3 Fuse Full Spectrum Endoscopy System. EndoChoice scientists and engineers worked together to develop Lumos based upon Adaptive Matrix Imaging which analyzes and selectively enhances the vascularity, surface texture, and color of abnormal tissue, providing detailed information for physicians to assist in their detection of abnormalities during GI procedures.
 
Lumos facilitates seamless physician detection and inspection of affected tissue by toggling between two settings. The first setting is designed to selectively enhance tissue and may remain on throughout the procedure, while the second setting allows for a more in-depth inspection once suspect tissue has been identified.
 
Lumos was launched in key international markets in February and physicians have already started seeing the benefit that Lumos can provide, according to the company. “Other image processing technologies alter the image, which can be distracting. With Lumos, only anatomy that has certain textures, vascularity or abnormal anatomy is enhanced, allowing me to keep my focus on potentially diseased tissue” said Peter Siersema, M.D. Ph.D., professor of Endoscopic Gastrointestinal Oncology at Radboud University Medical Center, Nijmegen, The Netherlands.
 
In a recent unpublished clinical study, physicians found that Lumos with Adaptive Matrix Imaging enhanced lesions with pit patterns and was useful as an aid in the detection of tissue abnormalities throughout the entire procedure. EndoChoice has multiple patents pending on this new technology.
 
“We are excited to introduce new innovations that continue to deliver on the Fuse brand promise of seeing more” said Mark Gilreath, founder and CEO of EndoChoice. “We expect that Lumos with Adaptive Matrix Imaging will become an indispensable tool for the GI endoscopist.”
 
Based near Atlanta, Ga., EndoChoice manufactures and commercializes platform technologies including endoscopic imaging systems, devices and infection control products and pathology services for specialists treating a wide range of gastrointestinal conditions, including colon cancer. EndoChoice leverages its direct sales organization to serve more than 2,500 customers in the United States and works with distribution partners in 30 countries. The company was founded in 2008 and has developed a product portfolio that includes the Full Spectrum Endoscopy System (Fuse).  EndoChoice, Fuse, and Full Spectrum Endoscopy are registered trademarks of EndoChoice Holdings Inc.